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Myelopoiesis is invariably present, and contributes to pathology, in animal models of graft versus host disease (GVHD).
In humans, a rich inflammatory infiltrate bearing macrophage markers has also been described in histological studies. In
order to determine the origin, functional properties and role in pathogenesis of these cells, we isolated single cell
suspensions from acute cutaneous GVHD and subjected them to genotype, transcriptome and in vitro functional analysis.
A donor-derived population of CD11c+CD14+ cells was the dominant population of all leukocytes in GVHD. Surface
phenotype and nanostring gene expression profiling indicated the closest steady-state counterpart of these cells to be
monocyte-derived macrophages. In GVHD, however, there was upregulation of monocyte antigens SIRPα and S100A8/9,
and transcripts associated with leukocyte trafficking, pattern recognition, antigen presentation, and co-stimulation.
Isolated GVHD macrophages stimulated greater proliferation and activation of allogeneic T cells, and secreted higher
levels of inflammatory cytokines than their steady-state counterparts. In HLA-matched mixed leukocyte reactions, we also
observed differentiation of activated macrophages with a similar phenotype. These exhibited cytopathicity to a cell line
and mediated pathological damage to skin explants, independently of T cells. Together, these results define the origin,
functional properties and potential pathogenic roles of human GVHD macrophages.
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Abstract 
Myelopoiesis is invariably present, and contributes to pathology, in animal models of 
graft versus host disease (GVHD).  In humans, a rich inflammatory infiltrate bearing 
macrophage markers has also been described in histological studies.  In order to 
determine the origin, functional properties and role in pathogenesis of these cells, we 
isolated single cell suspensions from acute cutaneous GVHD and subjected them to 
genotype, transcriptome and in vitro functional analysis.  A donor-derived population 
of CD11c+CD14+ cells was the dominant population of all leukocytes in GVHD.  
Surface phenotype and nanostring gene expression profiling indicated the closest 
steady-state counterpart of these cells to be monocyte-derived macrophages.  In 
GVHD, however, there was upregulation of monocyte antigens SIRPa and 
S100A8/9, and transcripts associated with leukocyte trafficking, pattern recognition, 
antigen presentation, and co-stimulation.  Isolated GVHD macrophages stimulated 
greater proliferation and activation of allogeneic T cells, and secreted higher levels of 
inflammatory cytokines than their steady-state counterparts.  In HLA-matched mixed 
leukocyte reactions, we also observed differentiation of activated macrophages with 
a similar phenotype.  These exhibited cytopathicity to a cell line and mediated 
pathological damage to skin explants, independently of T cells.  Together, these 
results define the origin, functional properties and potential pathogenic roles of 
human GVHD macrophages. 
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Introduction 
Acute graft versus host disease (GVHD) affects up to 50% of patients receiving 
allogeneic bone marrow transplantation (BMT) and remains a leading cause of 
morbidity and mortality (1, 2).  GVHD most commonly affects the skin, gut, liver, and 
may also contribute to idiopathic pneumonia syndrome (3).  In animal models, donor 
T lymphocytes play an essential role in immune-mediated damage to host epithelium 
(4).  In human GVHD, mononuclear infiltrates have been observed that include 
CD8+ T cells, CD4+ Th1, Th2, Th17, and Tregs although no pathognomic effector 
subset has been observed in all patient cohorts (5–8).  Despite the obvious 
importance of effector T cells, they may not be sufficient to mediate GVHD pathology 
(4).  In almost all GVHD models, pathology occurs in the presence of neutrophils, 
monocytes, and other myeloid components that may infiltrate tissues and amplify 
local immune responses (9). 
 
Animal models previously demonstrated that immunocompetent donor myeloid cells 
enhance GVHD, without specifying a particular cell type (10, 11).  Macrophages 
have been implicated through observations that GVHD may be modulated by 
manipulation of the M-CSF axis, although opposing effects have been reported, 
depending on the timing of interventions (12–15).  Glucocorticoids also appear to 
reduce GVHD at least partly through attenuation of macrophage responses (16) and 
in humanized mice, donor monocytes or DC are absolutely required for xeno-GVHD 
(17).  Knock-out of the ATP receptor P2Y2 on recipient monocytes reduces GVHD 
lethality (18).  Most recently, a specific role of T cell-derived GM-CSF was described 
in promoting the differentiation of effector macrophages (19). 
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In humans, a number of reports highlight an increase in myeloid cells bearing 
macrophage markers, showing that the level of infiltration correlates with clinical 
severity and outcome (7, 20, 21).  However, as shown by high resolution analysis, 
the myeloid cell compartment of human skin is highly complex with discrete 
populations of classical dendritic cells (DC), monocyte-derived cells, and resident 
macrophages, (22–26).  These observations suggest that the nature of myeloid 
infiltrates cannot be adequately resolved using in situ microscopy; hence their origin 
and immune functions in GVHD remain undefined. 
 
The role of (recipient) myeloid cells in responding to danger signals is integral to 
most models of GVHD but is not known whether human GVHD infiltrates bearing 
macrophage markers are recipient, donor, immunogenic or anti-inflammatory.   
Although donor myelopoiesis usually dominates the peripheral blood compartment 
during GVHD, recipient dermal macrophages have very slow kinetics of turnover in 
humans (22) and potentially expand during inflammation (27).   Macrophages are 
capable of mediating a wide spectrum of tolerogenic or pathogenic responses (28).   
By extrapolation from mouse models, macrophages are likely to promote GVHD.  
However, their ability to stimulate local effector T cells and mediate direct epithelial 
damage remain untested in humans.   
 
Here we employ direct methods of isolation and testing to show that acute GVHD 
lesions in human skin are dominated by CD11c+CD14+ myeloid cells with the 
genotype, phenotype, and transcriptional profile of donor monocyte-derived 
macrophages.  These cells have potent immunological functions that are likely to 
contribute to the pathogenesis of GVHD and may offer opportunities for therapeutic 
intervention.  
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Results 
In order to investigate the properties of myeloid cells in human cutaneous acute 
GVHD, mononuclear cells of the human dermis were defined by 
immunohistochemistry, immunofluorescence microscopy, and flow cytometry in 
healthy controls, BMT recipients without acute GVHD, and BMT recipients with 
GVHD (Table S1, S2).  BMT control patients without GVHD were biopsied on 
median day 83 post-transplantation (range 28-148 days).  GVHD skin biopsies were 
taken at the onset of an acute onset erythematous rash, prior to initiation of therapy.  
Classical acute GVHD, immunosuppression withdrawal acute GVHD, and acute 
GVHD following donor lymphocyte infusion were all included.  A pathological 
diagnosis of acute-type GVHD was confirmed by standard histological criteria in all 
cases and patients with clinical or histological features of chronic GVHD were 
excluded.  The median day of biopsy was day 53 (range 13-304; Mann-Whitney p = 
0.27 compared with BMT controls). In situ analysis showed an increase in CD3+ T 
cells and CD11c+ myeloid cells in a perivascular and epidermal interface distribution 
in GVHD (Figure 1A, B).  The nature of the leukocytic infiltrate was also 
documented using 4-color immunofluorescence of whole-mount specimens. There 
was marked infiltration of perivascular spaces by CD11c+ cells that usually remained 
distinct from FXIIIA-expressing resident macrophages (22) (Figure 1B).  Further 
comparison of CD11c, FXIIIA, and CD163 antigen expression by this approach is 
shown in Figure S1A-C.    
 
The infiltrates of acute GVHD infiltrate were characterized by flow cytometry of single 
cell suspensions.  Gating on live singlets expressing CD45 and HLA-DR revealed 
SSC low lymphocytes and HLA-DR+ SSC high myeloid cells as previously described 
(22, 25).  Surprisingly, the proportion of cells falling in the lymphoid gate was not 
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significantly increased in GVHD relative to BMT controls or healthy donors (Figure 
S1D, E) although a relative expansion of IFNg-secreting CD4+ T cells was observed 
in GVHD skin relative to healthy controls, this population was also elevated in BMT 
controls compared with healthy skin (Figure S1F).  Myeloid cells were further divided 
on the bivariate plot of CD14 versus CD11c allowing identification of subsets 
previously described in healthy control skin, without relying upon autofluorescence to 
capture resident macrophages (22–24, 26).  Cells captured in the CD14+CD11c+ 
gate correspond to cells captured in the autofluorescence negative, CD14+ gate 
previously described in healthy control skin  (25). The linkage between this new 
gating strategy and previously identified myeloid cell populations is explained in 
Figure S2A-D.   
 
 
In contrast to the modest changes in overall cellularity and T cell populations, 
CD11c+CD14+ myeloid cells were expanded more than 10-fold compared with 
healthy control skin or BMT skin without GVHD (Figure 1C, D, red gates; Figure 
S1A-C).  This GVHD-related subset lacked CD1c expression and mapped to 
autofluorescence negative, CD14+ parameter space containing monocyte-
macrophages in the steady-state (25).  Cells in the CD14+ CD11c- gate contained 
FXIIIA+ CD163+ macrophages with high melanin content and auto-fluorescence, 
representing ‘fixed’ or resident macrophages (22, 29, 30).  These were relatively 
depleted in GVHD as were classical DC2 (cDC2; CD11c+ CD1c+ CD14-) and cDC1 
(CD141+ cells in the CD14-CD11c- gate; Figure 1C, D).  The ratio of digested 
CD11c+ CD14+ cells to CD1c+ cDC2 was markedly increased in GVHD (Figure 1E) 
By ROC curve analysis, a ratio of >0.55 was 84% sensitive and 81% specific for the 
histological diagnosis of GVHD in skin biopsies post BMT (Figure 1F).  Sequential 
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biopsies showed resolution of the GVHD infiltrate in parallel with clinical 
improvement (Figure S2E, F).  
 
We sought to characterize the excess of CD11c+ CD14+ cells observed in GVHD 
further, showing by morphology that they were small macrophages with eccentric 
dense nuclei, cytoplasmic vacuoles, and granules, distinct from larger, melanin-rich 
macrophages isolated from the CD14+ CD11c- gates (Figure 2A).  They retained 
similar migratory capacity in vitro to their steady-state counterparts (25) (Figure 2B).  
An increase in the ratio of migratory CD11c+ CD14+ cells to CD1c+ cDC2, was also 
observed in GVHD (Figure 2C), as seen in digested preparations (Figure 1E).  
CD11c+CD14+ GVHD cells expressed common macrophage antigens (CD163, 
CD64, CD206, and CD209) but showed upregulation of monocyte-associated 
antigens (CD172a, S100A8/9, CD16 (Figure 2D). 
 
In order to define the ontogeny of CD11c+CD14+ cells relative to known populations 
of macrophages and DC, GVHD and steady state populations were sorted, and 
expression of 609 immunology-related genes was surveyed by Nanostring.  By 
principal component analysis (PCA), CD11c+CD14+ GVHD cells segregated with 
steady state monocyte-macrophages and resident dermal macrophages, away from 
DC populations (Figure 3A).   Focusing on a previously defined subset of 29 genes 
that distinguish between DC and monocytes/macrophage lineages (25), 
CD11c+CD14+ GVHD cells clustered with steady-state monocyte-macrophages and 
resident macrophages in unsupervised analysis (Figure 3B).  Genotype analysis by 
XY FISH in sex-mismatched transplants showed a median of 98-100% donor origin 
of CD11+CD14+ GVHD macrophages, equal to the level of blood myeloid chimerism 
(Figure 3C, D).  Based on these results, we conclude that CD11c+CD14+ myeloid 
cells in GVHD are donor monocyte-derived macrophages.  Recipient T cells were 
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present in the dermis in 3 out of 4 patients at the time of GVHD.  Although myeloid 
cells have previously been described in human GVHD by histology, their functional 
properties have not been directly tested.  Steady-state CD14+ monocyte-derived 
macrophages are not potent allo-stimulators compared with dermal CD141+ cDC1 
and CD1c+ cDC2 (22, 23).  In contrast, GVHD macrophages were capable of 
stimulating T cell proliferation and expression of activation antigens to the level 
associated with steady-state DC populations (Figure 4A, B).  Gene expression 
profiling of 2,000-5,000 sorted cells, revealed upregulation of allo-stimulatory 
functions included antigen presentation (HLA, TAP1), recruitment (CCL24), and 
stimulation of lymphocytes (CD82), stimulation of pro-inflammatory cytokines 
(SPP1), and leukocyte extravasation (SELPLG) (Figure 4C).  Differential expression 
of several key chemokines and cytokines was also revealed at the protein level, 
including CCL5/RANTES, CXCL10, IL-8, TNFb, and IL-10 (Figure 4D). 
 
The presence of prominent monocyte-derived populations in human GVHD 
prompted us to examine the peripheral blood for evidence of altered myelopoiesis or 
priming of monocytes.  Classical monocytes were enriched in patients with GVHD, 
especially in proportion to CD1c+ cDC2, as described in GVHD skin (Figure 5A, B).  
Analysis of differential gene expression between the monocytes of patients with 
GVHD and healthy controls, showed upregulation of monocyte chemoattractant 
receptor CCR5, MRC1 (macrophage mannose receptor, CD206), FCGR3A/B Fc 
receptor/CD16), GNLY (Granulysin) and interferon-response genes IFITM1 and 
GBP1 (Figure 5C).  Down-regulation of a large module of genes associated with DC 
differentiation such as FCER1A, IRF4, ZBTB46 and CIITA. 
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In addition to monocyte priming, whole skin gene expression of GVHD-affected skin 
showed prominent upregulation of monocyte (and T cell) chemokine receptor-ligand 
pairs (Figure 5D).  The proportion of CD14+ CD11c+ GVHD macrophages found in 
affected skin mirrored the relative expansion of CD14+ monocytes in the blood 
(Figure 5E). 
 
The preceding data suggest that GVHD macrophages are donor-derived from blood 
monocytes and achieve a higher state of functional activation than their steady state 
counterparts.  Further evidence of their likely function in GVHD was sought by 
deriving allo-stimulated macrophages from monocytes and testing their functional 
properties.  HLA-matched donor and recipient blood was taken prior to 
transplantation and PBMC stored in order to prepare mixed leukocyte reactions.  The 
cytokine milieu of an HLA-matched MLR was similar to that observed when GVHD 
skin was cultured (Figure 6A), and a prominent population of macrophages 
appeared, with similar phenotype to GVHD macrophages (Figure 6B, C).  118 
transcripts were differentially expressed between monocytes and MLR-derived 
macrophages (FDR ≤0.05; Table S3, supplementary data and Figure S3).  MRC1, 
CCR5 and PPBP, upregulated in GVHD macrophages in vivo, were also highly 
upregulated in MLR macrophages.  MLR-activated macrophages also expressed 
cytotoxic molecules perforin, granzyme A, granulolysin, and TRAIL, similarly to 
GVHD macrophages (Figure 6D).  Many of these products were already upregulated 
in CD14+ monocytes isolated from the blood of patients with GVHD, compared with 
healthy control monocytes (Figure 6D). 
 
The expression of cytotoxic molecules prompted us to test the possibility that MLR-
activated macrophages might mediate cytotoxicity to epidermal cells.  We observed 
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that MLR-activated macrophages were directly cytotoxic to a keratinocyte cell line in 
vitro, in a dose-dependent manner (Figure 7a, b).  In order to test a setting more 
relevant to GVHD, we adapted the in vitro skin explant model.  When a small explant 
of intact skin is exposed to a clone of minor-histocompatibility antigen-specific T 
cells, GVHD-like epidermal pathology is observed in an HLA-restricted and antigen-
specific manner (31).  GVHD pathology is also observed, in proportion to HLA-
matching and sex differences, when recipient skin is exposed to donor leukocytes 
pre-sensitized to recipient antigens in a mixed leukocyte reaction (MLR) (32).  
Although it has been assumed that GVHD pathology in vitro is exclusively mediated 
by T cells in the MLR, we were surprised to observe nearly equivalent cytopathic 
effects when the ‘donor’ MLR was sorted into macrophage and T cell components 
(Figure 7c, d). 
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Discussion 
In this study we have defined the role of myeloid cells in human cutaneous acute 
GVHD by characterizing mononuclear infiltrates from primary tissue, isolating the 
dominant myeloid cell, defining its origin, transcriptional profile, and functional 
properties.   The data indicate that human GVHD lesions are highly infiltrated with 
donor monocyte-derived macrophages with enhanced allo-stimulatory activity and 
the potential to mediate epidermal pathology.   
 
Myeloid cells found in GVHD have previously been characterized as macrophages 
based on descriptive histopathology with a small number of surface antigens.  These 
studies lack further details of the biological characteristics or potential pathogenic 
role of macrophages in GVHD (7, 20–22).  Indeed, evidence that macrophages 
enhance local effector immune functions is surprisingly hard to find in any scenario 
of inflammation in human tissues.  Where they have been isolated from primary 
human tissues, their function has been described as regulatory, in comparison with 
DC (33, 34).  Our findings that GVHD macrophages have functional attributes 
capable of promoting GVHD provide an important corroboration of recent mouse 
models describing the dependence of GVHD pathology upon donor myeloid cells 
activated by T cell-derived GM-CSF (19).   
 
Numerically, macrophages show the greatest fold increase in GVHD of any 
mononuclear cell and constitute the most consistent ‘cellular signature’ of acute 
GVHD relative to recipients without GVHD or healthy control skin.  The 
macrophage:DC ratio is sensitive and specific relative to BMT control skin without 
GVHD, increasing more than 100-fold in the presence of GVHD.  Previous studies of 
human GVHD have placed emphasis upon the potential existence of a 
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pathognomonic subset of T cells in GVHD, although none has been consistently 
identified (6–8).  Unlike animal models of BMT in which additional splenic T cells are 
added to initiate GVHD (4), human BMT recipients are typically severely 
lymphopenic owing to the routine use of T cell depletion strategies, calcineurin 
inhibitors, and anti-metabolites such as methotrexate.  Numerically, the T cell 
infiltrate is surprisingly modest and insignificantly different to healthy human skin, 
especially in classical early acute GVHD.  The observations that MHC class I and II 
mismatches both increase the risk of GVHD and that CD4 or CD8 selective depletion 
does not abrogate GVHD are in keeping with multiple pathways of T cell 
alloreactivity that may vary from patient to patient (4).  The striking feature is that all 
appear to result in the profound recruitment of inflammatory macrophages.   
 
Here, GVHD macrophages were defined as CD11c+CD14+ cells, based on the most 
direct means of distinguishing the infiltrate from auto-fluorescent CD11c- resident 
macrophages by flow cytometry.  Several lines of evidence point to a monocyte 
origin; most notably they are donor-derived and therefore unlikely to arise by 
proliferation of resident recipient macrophages.  Additional staining demonstrated 
high expression of monocyte antigens S100A8/A9 and SIRPA (CD172), consistent 
with recent emigration of monocytes from the blood (35, 36).  Nanostring gene 
expression analysis confirmed transcription of a core set of macrophage-related 
genes including MAF, MERTK, F13A1, CD163, and CD14.  Although GVHD 
macrophages have higher expression of monocyte antigens and a number of 
important functional differences, they are most closely related to CD11c+CD14+ 
dermal cells found in steady-state tissues and previously reported to have a 
transient, monocyte origin (25).  Enhanced monocyte priming and recruitment to 
tissues is also suggested by the phenotypic activation of peripheral blood 
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monocytes, previously reported in patients with active GVHD (37–39).  We observed 
a similar phenomenon in the expression of cytotoxic genes by GVHD monocytes 
compared with those from healthy controls.  In corroboration, we also observed that 
monocytes differentiating into macrophages in HLA-matched MLRs had a similar 
phenotype and functional properties to GVHD macrophages. 
 
The data indicate that single surface markers previously used to define GVHD 
macrophages by histology often have variable expression under more detailed 
scrutiny.  In keeping with previous reports (7, 20–22), CD163 was detectable by flow 
cytometry, but was less consistent than CD11c+ in identifying GVHD infiltrates by 
immunohistochemistry.  CD163 is expressed by resident macrophages (40) and 
chronic inflammatory macrophages found in psoriasis (41), coeliac disease (42) (43), 
and Crohn’s disease (44).  In coeliac disease, acute gluten challenge induces an 
increase of CD11c+CD14+ cells with modest expression of CD163 (43), reminiscent 
of the population we describe in GVHD, suggesting that similar pathways of 
inflammatory myeloid cell recruitment operate in other conditions.  Higher CD163 
expression was associated with longer intervals post-transplant, consistent with 
previous descriptions of abundant CD163 expression in advanced GVHD lesions 
(20, 21).  These findings are also in keeping with the original characterization of 
CD163 (clone RM3/1) as a ‘late phase’ macrophage antigen with more delayed 
kinetics of expression (45). 
 
GVHD macrophages demonstrated enhanced T cell stimulatory functions, compared 
with steady-state CD11c+CD14+ cells, including greater expression of pattern 
recognition, leukocyte adhesion and trafficking, antigen presentation and T cell co-
stimulation genes, production of chemokines, and capacity to stimulate allogeneic T 
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cell proliferation.  Ideally, these functions would have been compared with 
CD11c+CD14+ cells isolated from BMT controls but this was not possible owing to 
the paucity of these in small clinical biopsies of skin unaffected by GVHD, as shown 
in in Figure 1.  However, even steady-state CD11c+CD14+ cells already 
demonstrate upregulation of cytotoxic molecules, compared with blood monocytes 
suggesting that they exist in a poised state potentially governed by mediators that 
are further upregulated during GVHD, such as IFNg (46).  The potential of 
macrophages to mediate direct cytotoxic effects is described in classical studies but, 
until recently, has received little attention in the field of GVHD.  Early studies showed 
that GVHD induced priming of macrophages resulting in direct cytotoxicity following 
LPS challenge (47) and subsequent work elaborated on the secretory properties of 
activated macrophages (48).  However, contemporary models of GVHD present the 
contribution of macrophages to GVHD almost exclusively in terms of sensing danger 
and enhancing accessory cell function (9–11).  It was not possible to harvest 
sufficient GVHD macrophages directly from biopsies to test their effector function so 
we generated allo-stimulated macrophages from monocytes in HLA-matched MLRs, 
as a surrogate.  MLR-stimulated macrophages were capable of mediating direct 
cytopathicity with a cell line and surprisingly, caused a similar degree of 
immunopathology as T cells in the skin explant model of GVHD.  Although the latter 
lacks all the complexity of GVHD in vivo, it is the only fully human system amenable 
to manipulation.  Furthermore, the degree of pathological damage consistently 
reflects levels of major and minor histocompatibility antigen matching and has been 
used previously to dissect HLA-restricted antigen-specific GVHD responses (31, 32).  
This result revises the assumption that T cells are the only relevant effectors when 
the MLR product is added to explanted skin. 
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In classical animal models of GVHD, myelopoiesis is invariable present during the 
effector phase of GVHD, even when the sole instigator of GVHD is a T cell clone 
directly targeted to epithelium (49, 50).  Investigators have now revealed non-
redundant functions for myeloid cells in GVHD pathogenesis (12–15, 17, 19).  The 
conceptual advance that T cells are necessary but may not be sufficient for GVHD 
has important therapeutic implications.  Unlike T cells in the human adult, which may 
take more than 2 years to recover after transplantation, myeloid cells are 
continuously generated, and rapid immune reconstitution is possible following 
myeloid-targeted interventions.  The ability to isolate discrete mechanisms that 
govern the infiltration of tissues by myeloid cells, such as GM-CSF dependence, may 
also offer a means of minimizing GVHD without compromising GVL (19). 
 
As described in the accompanying manuscript by Divito et al. (51), host tissues 
affected by GVHD such as the skin and gut contain a significant proportion of host 
resident T cells that survive for many months and are found in an activated state in 
association with donor macrophages.  Our results support the conclusion that donor-
derived macrophages have enhanced antigen presenting functions that could enable 
the activation of residual host T cells resulting in host-versus-graft responses that 
may be indistinguishable from GVHD clinically.  Recent observations in patients with 
host versus graft mismatches are consistent with this.  A proportion of HLA-DP 
mismatching occurs exclusively in the host versus graft direction (heterozygous 
donor to homozygous recipient) and, surprisingly these patients have a high 
incidence of grade I GVHD (Reid et al, manuscript in preparation).  Further studies 
will be required to determine whether the marked difference in outcome between 
low-risk grade I acute GVHD, and ‘clinically significant’ grade II-IV acute GVHD 
reflects fundamental differences in mechanism.   It is entirely plausible that many 
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patients experience a self-limiting reaction of host T cells resulting in skin-limited 
disease responsive to topical corticosteroids, while the canonical recruitment and 
activation of donor T cells only comes into play in higher grade disease.  We have 
shown that donor macrophages are capable of performing both antigen-presenting 
and cytotoxic functions but these may also be differentially involved depending on 
whether inflammation is primarily driven by recipient or donor T cells.  Divito et al 
observe that skin and gut both have prominent populations of resident T cells and it 
will be important to explore the potential of donor macrophages to activate host T 
cells in gut GVHD.  
 
The evidence that donor-derived macrophages perform essential functions in GVHD 
in both mouse and humans, contrasts with continuing uncertainty over the role 
played by recipient antigen-presenting cells.  Although it is possible to construct 
mouse models in which GVHD depends solely on recipient myeloid cells or specific 
populations such as Langerhans cells (52–54), other models show that Langerhans 
cells (55), or indeed any hematopoietic antigen presenting cell, are not required for 
GVHD (56).  In human correlative studies, GVHD promotes donor myeloid cell 
engraftment, so the occurrence of GVHD is invariably associated with a loss of 
recipient antigen-presenting cells (57).  Although human Langerhans cells are self-
renewing (29, 58, 59) this potential is insufficient to maintain them after 
transplantation; even with non-myeloablative conditioning they become almost fully 
donor-derived in about 3 months, (60). 
 
In summary, the results presented here demonstrate that GVHD lesions contain 
abundant donor macrophages, likely to be derived from activated circulating classical 
monocytes.  GVHD macrophages secrete chemokines, stimulate T cells, and 
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mediate direct cytotoxicity. Together, these results shed new light on human 
macrophage functions that are exploitable for the prevention and treatment GVHD. 
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Methods 
Human subjects  
Sequential patients undergoing allogeneic BMT were recruited from the Northern 
Centre for Bone Marrow Transplantation at Newcastle upon Tyne Hospitals NHS 
Foundation Trust over a 3-year period between 2013 and 2016.  5-15mm2 skin 
shaves were obtained using 1% lidocaine local anesthesia and a DermabladeTM from 
BMT recipients were biopsied at the onset of a rash clinically compatible with GVHD.  
An independent clinical pathologist provided diagnosis and histological grading of 
GVHD.  BMT recipient controls with no evidence of any rash were biopsied when 
attending for routine assessments at day +28 or day +100 post-transplant.  Biopsies 
were transported in serum-free medium (X-VIVO, Lonza) and analysed within 24 
hours.  An independent clinical pathologist provided diagnosis and histological 
grading of GVHD in controls and GVHD biopsies.  Healthy control skin was obtained 
from patients undergoing mammoplasty or abdominoplasty as previously described 
(22).  Specimens comparable to clinical biopsies were obtained by immobilizing skin 
strips on a cork block covered with sterile silicon and performing skin shave biopsies. 
 
Cell lines and mononuclear cells 
Unless stated otherwise all cells were cultured in RPMI 1640 (Lonza) with 100IU/ml 
penicillin, 10μ/ml streptomycin, 2mM L-glutamine  (Invitrogen), 10% heat-inactivated 
fetal bovine serum (Sera Lab). MLR macrophages were generated from co-culture of 
peripheral blood mononuclear cells (PBMCs) from HLA-matched BMT donor and 
recipient pairs.  Recipient PBMCs were irradiated (20Gy) and used as stimulators for 
donor PBMCs at a 1:1 ratio.  Cultures containing 1-5x107 donor PBMCs were 
maintained in RPMI 1640 with 10% human AB serum (Sigma) for 7 days.  HaCaT 
cells were obtained from Accegen. 
Jardine 2019 133909-JCI-RG-RV-2 
 
20 
20 
 
Enzymatic digestion of skin biopsies 
Skin shave biopsies were used whole or split into dermis and epidermis by treatment 
with dispase 0.5-1.0mg/ml in RPMI for 60-90 minutes at 37°C (Gibco) before 
digestion in medium with 1.6mg/ml type IV collagenase (Worthington) for 12-16 
hours at 37°C in RPMI with 10% heat-inactivated fetal calf serum.  Gentle 
dissociation and passage through a 100μm filter generated single cell suspensions.   
 
Migration of cells from skin biopsies 
For some experiments, an enzyme-free preparation of leukocytes was required. Skin 
was cultured as above but without collagenase. After 48 hours, migratory leukocytes 
were harvested from the supernatant.  Supernatants were stored at -80°C and later 
used for cytokine analysis by Luminex assay (see below) 
 
Immunohistochemistry 
Formalin-fixed and paraffin-embedded skin shave biopsies from GVHD diagnostic 
material were used.  4μm sections were made.  Antigen retrieval and staining were 
performed using the BenchMark autostainer (Ventana). CD3, CD163, CD11c, factor 
XIII and Ki67 primary antibodies and the ‘ultraview’ detection kit were used (Roche). 
 
Fluorescence microscopy 
Antibodies used for microscopy are listed in Table S4.  200μm sheets of whole skin 
were fixed in 2% paraformaldehyde (Sigma-Aldrich) and 30% sucrose (Sigma-
Aldrich) in PBS (Gibco) for 12-18 hours at 4°C, washed in PBS and stored at 4°C 
until staining.  Specimens were blocked in 0.5% bovine serum albumin (Sigma-
Aldrich) with 0.3% TritonX-100 (Thermo Fisher Scientific) in PBS and stained at 4°C 
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for 12-18 hours with the following primary/secondary combinations:  CD11c-
biotin/Streptavidin Cy5; Factor XIII/donkey anti-sheep Alexa Fluor 647; CD3/donkey 
anti-mouse Alexa Fluor488. Sections were immersed in DAPI-containing mounting 
medium for 12-18 hours at 4°C, then visualized on a Zeiss Axioimager Z2 using the 
Apotome function and Axiovision version 4.8 software. 
 
Flow cytometry analysis and sorting 
Antibodies used for flow cytometry are listed in Table S4.  DAPI was added for dead 
cell discrimination (Sigma).  Flow cytometry analysis and sorting was performed 
using BD FACS Canto II, BD Fortessa X20, BD FACS Aria II and BD FACS Fusion 
running FACSDiva version 7 and analyzed with FlowJo V10 (TreeStar). 
 
X/Y fluorescence in situ hybridization 
Sorted cells were spun onto slides, fixed in methanol and acetic acid and prepared 
with dual labeled XY FISH probes on a ThermoBrite system (Abbott) in accordance 
with manufacturer’s instructions. 
 
Gene expression by NanoString 
Gene expression was quantified by NanoString, using the Human Immunology v2 
panel with a custom 30-gene add-on targeting monocyte/macrophage and DC genes 
(ASIP, C19orf59, CCL17, CD1C, CD207, CLEC10A, CLEC9A, CLNK, COBLL1, 
CXCL5, DBN1, F13A1, FGD6, FLT3, GCSAM, GGT5, Ki67, LPAR2, LYVE1, MAFF, 
MERTK, NDRG2, PACSIN1, PPM1N, PRAM1, S100A12, SIRPA ,TMEM14A, 
UPK3A and ZBTB46).  3,000-10,000 sorted cells were pelleted and lysed in 5μl RLT 
buffer (Qiagen) + 1% beta- mercaptoethanol yielding 50-150ng total RNA for 
analysis.  Hybridization was performed according to manufacturer’s instructions 
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using a NanoString Prep Station and Digital Analyzer. nSolver Analysis software 
version 3.0 was used for background correction and normalization. 
 
Lymphocyte proliferation assays 
Healthy volunteer T cells were prepared from healthy blood donors by 
immunodensity negative selection (Human T cell enrichment cocktail, Stemcell 
15021) and labeled with 1μM CSFE (Invitrogen).  T cells were co-cultured with 
sorted macrophages or DCs at a 25:1 ratio for 7 days, incubated with antibodies to 
CD3, CD4, CD8, HLA-DR and CD69 (Table S3), and analyzed by flow cytometry. 
 
Cytokine and chemokine quantification 
Quantification was performed on medium from isolated macrophage populations 
stimulated ex-vivo and medium conditioned by explanted GVHD skin and by donor-
recipient MLR.  For macrophage stimulation, FACS sorted skin macrophages were 
stimulated with 100ng/ml LPS from E. coli (Sigma) and harvested at 10 hours.  
Supernatants were cryopreserved at -80°C and batch-analyzed by Luminex assay 
(ProcartaPlexTM 34-plex, EBioscience) using a Qiagen Liquichip 200 running 
Luminex 100 integrated system software version 2.3. Procartaplex Analyst version 
1.0 was used to define standard curves. 
 
Skin explant assay 
Blood from BMT donor and recipient pairs was prospectively collected into EDTA, 
prior to transplnatation.  Recipient PBMCs were irradiated (20Gy) and used as 
stimulators for donor PBMCs at a 1:1 ratio.  Cultures containing 1-5x107 donor 
PBMCs were maintained in RPMI with 10% human AB serum (Sigma) for 7 days.  
Macrophages and T cells were sorted from MLR outputs as HLA-
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DR+CD14+CD11c+ cells and SSCloCD3+ cells respectively.  Shave biopsies of 
recipient skin were taken prior to BMT conditioning.  Biopsies were divided and 
incubated with medium alone (negative control), 2x105 MLR lymphocytes or 2x105 
MLR macrophages for 3 days in RPMI 1640 with 20% heat inactivated autologous 
serum.  Explants were fixed in 10% buffered formalin, sectioned and stained with 
haematoxylin and eosin.  Severity of histological damage was graded using the 
Lerner scale by an experienced assessor blinded to experimental conditions (XN 
Wang). 
 
Quantification and statistical analysis 
FlowJo version 9.6.7 was used for analysis of flow cytometry data.  Principal 
component analysis (PCA), hierarchical clustering and unpaired 2-tailed t-tests were 
performed in MultiExperiment Viewer software version 4.8 (Saeed et al., 2003).  
One-way ANOVA and other statistical analyses were performed in GraphPad Prism, 
version 7.0.  A p value of <0.05 was considered significant.  Additional details of 
statistical methods used are provided in figure legends. 
 
Study approval 
All human samples were obtained with informed consent according to the protocols: 
Improving Haematopoietic Stem cell Transplantation Outcome, Newcastle and North 
Tyneside Research Ethics Committee 2 reference 14/NE/1136; or Newcastle 
Biobank, Newcastle and North Tyneside Research Ethics Committee 1 reference 
17/NE/0361.   
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Fig. 1. Mononuclear infiltrates in GVHD contain abundant CD14+CD11c+ 
myeloid cells.  
Microscopic and flow cytometric evaluation of cutaneous GVHD lesions. 
Abbreviations: HC: healthy controls; BMT: patients without GVHD; GVHD: patients 
with GVHD 
A. Acute GVHD (top row) and healthy control skin (bottom row).  
Immunohistochemistry with antibodies to CD3, CD11c, CD163 and factor XIIIa (red 
chromagen) co-stained with antibody to Ki67 (brown chromagen). Scale bar 100µm. 
B. Whole mount immunofluorescence of dermis from HC and GVHD as indicated 
with antibodies to CD3 (red) CD11c (green) and FXIIIA (Blue).  Scale bar 50µm. 
C. Enzymatically digested dermis analyzed by flow cytometry from GVHD, BMT or 
HC as indicated.  Starting from CD45+ mononuclear cells (purple gate), HLA-DR+ 
cells were gated as shown to arrive at CD11c-CD14+ resident macrophages 
(brown), CD11c+CD14+CD1c- monocyte-macrophages (red), CD11c+CD14+CD1c+ 
double positive cells (pink), CD1c+CD14- cDC2 (cyan) and CD141+ cDC1 (yellow; 
from the CD14-CD11c-gate).  Representative samples of more than 60 experiments 
are shown. 
D. Quantification of digested dermal mononuclear cells from patients with GVHD 
(n=39), BMT (n=16) or HC (n=21) as a percentage of live cells.  Mean and SEM for 
each group is shown.  Groups were compared by one-way ANOVA and p-values 
from Tukey’s multiple comparisons tests are shown:  * p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
E. Ratio of CD11c+CD14+ cells to CD1c+CD14- cells in digests of GVHD, BMT 
control or healthy control dermis (14:1c ratio).  Median and interquartile range for 
each group is shown.  Groups were compared by Kruskal-Wallis test and p-values 
from Dunn’s multiple comparisons test are shown. 
F. ROC curve analysis of 14:1c ratio in digested cells from GVHD versus BMT 
controls.  Area under the curve=0.85.  Maximal sensitivity and specificity at occurred 
at a ratio of >0.55. 
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Fig. 2. CD14+CD11c+ cells are small migratory macrophages with monocyte 
antigen expression.  
A. May-Grünwald Giemsa stained cytospins of CD11c+CD14+ and CD11c-CD14+ 
myeloid cells sorted from GVHD dermis and healthy controls.  Representative cells 
from 2-4 concatenated images are shown.  Scale bar represents 20 μm.  
B.  Flow cytometry analysis of CD45+HLA-DR+ leukocytes migrating from explanted 
GVHD or healthy control skin over 48 hours in vitro.  Gating as in Figure 1. 
C. Comparison of CD14:CD1c ratio in migrating cells from GVHD skin (n=14) and 
healthy controls (n=6).  Bars show mean ± SEM.  *** p=0.0002 by Mann-Whitney 
test.  
D. Relative expression of selected antigens on CD11c+CD14+ cells migrating from 
GVHD skin (red line) or healthy control (blue line) compared with isotype control 
(grey line).  Representative data from at least three donors are shown. 
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Figure 3. CD14+CD11c+ myeloid cells are donor-derived macrophages.  
A. Principal component analysis (PCA) of immune gene expression by 
CD11c+CD14+ GVHD cells and 6 myeloid subsets from healthy control skin.  
Myeloid cells were sorted from healthy control skin as described in Figure 1 and are 
annotated accordingly. 
B.  Heat map showing unsupervised clustering of CD11c+CD14+ cells from GVHD 
skin and myeloid cells derived from healthy control skin.  Mean log2 expression for 
each subset is shown (n=2 for CD141+, n=3-6 for all other subsets). 
C. Example of FISH showing the XY genotype of GVHD macrophages (CD11c+ 
CD14+) and lymphocytes sorted from a female recipient transplanted with a male 
donor.  A single field viewed at 10x magnification was concatenated to show 8 
representative cells per image.  Scale bar represents 20 μm. 
D. Percentage donor origin analyzed by XY FISH of macrophages (M) and 
lymphocytes (L) sorted from lesional GVHD skin compared with CD15+ myeloid cells 
(CD15+) and lymphocytes (CD3+) sorted from paired blood samples.  
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Fig 4. GVHD macrophages activate allogeneic T cells  
A. proliferation of allogeneic CD4 and CD8 cells estimated by CFSE dilution after co-
culture with DC and macrophage subsets sorted from GVHD or healthy controls  
B. summary of T cell proliferation (% CFSE dilution) and activation (% CD69+ CD8+ 
T cells and % HLA-DR+ CD4+ T cells) from n=3 experiments. *p<0.05 by unpaired t-
test. 
C. Heatmap of genes differentially expressed between CD11c+CD14+ monocyte-
derived macrophages cells sorted from HC skin (n=4) and GVHD skin (n=3) with fold 
difference in log2 gene expression >1.3 and p<0.05 by unpaired t-test.  Annotations 
show functional attributes of genes (based on Entrez gene summaries) upregulated 
in GVHD macrophages  
D. CD11c+CD14+ monocyte-derived macrophages sorted from GVHD (n=3) and 
healthy control dermis (n=4) were stimulated with LPS in culture over 10 hours.  
Chemokine and cytokine production was quantified in supernatants by Luminex 
assay.  Bars show mean ± SEM.  By unpaired t-test * denotes p<0.05 and *** 
denotes p<0.001.  
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Fig 5. Monocytes are poised to differentiate into GVHD macrophages  
A. Comparison of peripheral blood mononuclear cells of healthy control (HC), 
transplant patients without GVHD (BMT) and with GVHD (GVHD).  CD3-CD4+HLA-
DR+ monocyte and DC populations were divided into CD14+ classical monocytes 
and CD14-CD16- DC including CD123+CD11clo pDC, CD141+ cDC1 and CD1c+ 
cDC2.  Representative examples of 10 experiments are shown.  Frequency of gated 
CD14+ monocytes and CD1c+ cDC2 is indicated as a percentage of HLA-DR+ cells. 
B. Ratio of CD14+ monocytes to CD1c+ cDC2 in blood of GVHD patients (n=15), 
BMT controls (n=16) and healthy controls (n=15) analyzed by flow cytometry as 
shown in panel A.  Bars represent mean and SEM; p values from one-way ANOVA 
and Tukey’s multiple comparison tests shown: * p<0.05; ** p<0.01. 
C. Genes differentially expressed between healthy control monocytes (upregulated 
in purple) and GVHD classical monocytes (upregulated in red) at fold difference in 
log2 gene expression >1.3 and p<0.05.  Cells sorted from n=6 GVHD and n=3 HC 
individuals.  
D. Radial plot showing mean expression of chemokine genes in whole skin from 
patients with GVHD (red line; n = 10) and healthy controls (blue line; n = 6).  
Expression of the corresponding receptors by monocyte, T cell, or both is indicated 
E. Correlation between blood CD14+ monocyte frequency and CD11c+CD14+ 
content of GVHD dermis in paired blood and skin samples from 10 patients with 
GVHD. Statistical test by linear regression. 
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Fig 6: Allo-stimulated monocytes resemble GVHD macrophages 
 
A. Radial plots of cytokine quantity in supernatants from GVHD explants cultured for 
48 hours (red line) and BMT donor-recipient MLRs cultured for 7 days (purple line).  
Lines show mean cytokine concentration from n=12 (GVHD) and n=6 (MLR) 
experiments.  IL-9, IL12p70, IL-23, IL-31 and TNF-β, are not shown because they 
were not detected in any specimens.  
B. May-Grünwald Giemsa cytospin morphology, scatter properties and CD11c/CD14 
expression by MLR macrophages, isolated on day 7.  Scale bar represents 20 μM.  
C. Expression of selected antigens, previously used to define GVHD macrophages, 
by allo-stimulated CD11c+CD14+ cells from BMT donor-recipient MLRs (purple line; 
isotype: gray line) Representative histograms from more than 3 analyses are shown.  
D. Expression of cytotoxic effector genes in CD14+ blood monocytes, skin 
CD11c+CD14+ cells and MLR macrophages.  Columns indicate mean and bars 
SEM of n=3-6 values; * * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Kruskal-Wallis test with p values from Dunn’s multiple comparison tests are shown. 
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Figure 7. Cytoxicity of allo-activated macrophages in vitro 
A. Direct cytotoxicity of MLR macrophages to the keratinocyte cell line HaCaT was 
assessed by co-culture of HaCaT and MLR macrophages at a range of effector to 
target ratios for 5 hours. Keratinocytes were identified as CD45- cells by flow 
cytometry and the proportion of dead keratinocytes quantified by Annexin-V and 7-
AAD staining.  Representative flow cytometry plots from keratinocytes alone (top 
row) and keratinocytes cultured with MLR macrophages at a 50:1 ratio (bottom row).   
B. Quantitation of keratinocyte apoptosis versus effector: target ratio in two 
independent experiments. 
C. Experiments using the skin explant model of GVHD (see Methods for details) 
MLR outputs were sorted to yield macrophages (mac) and lymphocytes (lymph) and 
co-cultured with shave biopsies of recipient skin for 3 days.  Explants were fixed and 
stained with Haematoxylin and eosin.  Representative images from explants cultured 
for 3 days in control medium or medium with MLR macrophages, as indicated. 
D. Summary of histological damage to the dermo-epidermal junction graded on the 
Lerner scale from 6 independent experiments; ** p <0.01 from Kruskal-Wallis and 
Dunn’s multiple comparison tests are shown. 
 
 
